UBS Group AG
- SEC CIK
- 0001610520
- Latest filing
- Aug 13, 2026
ERNA holding history
Ernexa Therapeutics Inc. in every 13F filed by UBS Group AG, including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
ERNA overviewAll 13F holders of ERNAFull Q2 2026 holdings
- Shares (Q2 2026)
- 0
- Sold out in Q2 2026
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 9
- Since Q1 2023
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q2 2026 | 0 | $0 | 0.0% | −21,233−100.0% | Sold out | Holders |
| Q1 2026 | 21,233 | $4.22K | <0.1% | +20,633+3,438.8% | Added | Holders |
| Q4 2025 | 600 | $720 | <0.1% | +600 | New | Holders |
| Q3 2025 | 0 | $0 | 0.0% | −548−100.0% | Sold out | Holders |
| Q2 2025 | 548 | $1.01K | <0.1% | −284−34.1% | ReducedConverted for a 1-for-15 split | Holders |
| Q1 2025 | 12,473 | $2.22K | <0.1% | −4,384−26.0% | Reduced | Holders |
| Q4 2024 | 16,857 | $4.96K | <0.1% | −66,763−79.8% | Reduced | Holders |
| Q3 2024 | 83,620 | $87.8K | <0.1% | +83,620 | New | Holders |
| Q2 2024 | 0 | $0 | 0.0% | −741−100.0% | Sold out | Holders |
| Q1 2024 | 741 | $1.78K | <0.1% | +741 | New | Holders |
| Q4 2023 | 0 | $0 | 0.0% | −105−100.0% | Sold out | Holders |
| Q3 2023 | 105 | $229 | <0.1% | +105 | New | Holders |
| Q2 2023 | 0 | $0 | 0.0% | −3,864−100.0% | Sold out | Holders |
| Q1 2023 | 3,864 | $13.1K | <0.1% | +3,864 | New | Holders |